Shahina Mukadam, Independent Market Expert is of the view that one may exit Wockhardt on bounce.
"In terms of a valuation I would say it is in line with the midcap pharma. If you look at it in current price it is still about 18-19 times FY17 earnings. I don’t see one reason why one should stay in the stock. One should definitely switch from this stock to some other similar mid to largecap pharma stocks, which I expect to do better over the next two years," she added.